The case for & against
Bull & Bear analysis
Tilray Brands (NASDAQ: TLRY) is a leading player in the cannabis and wellness sectors, known for its diverse portfolio that includes cannabis products, craft beverages, hemp-based foods, and wellness offerings. The company leverages its expansive footprint and product variety to cater to a wide range of consumer markets, allowing it to capitalize on the growing acceptance of cannabis products. With recent expansions into medical cannabis markets in Latin America and new product lines in its beverage segment, Tilray aims to strengthen its position in both established and emerging markets.
Bull says
- ↑Panama medical cannabis launch expected to expand LATAM revenue base.
- ↑BrewDog acquisition and Breck Vodka Seltzer launch diversify RTD beverage segment.
- ↑Q3 2026 revenue projected up 19.4% to $268.2M despite EPS weakness.
- ↑Book-to-price ratio at 1.44 suggests undervaluation relative to assets.
- ↑0.69% dividend yield offers shareholder income amid growth strategy.
- ↑Positive analyst revisions signal upward earnings expectations.
Bear says
- ↓Unprofitability persists, with EPS projected to fall 105% YoY to -$0.01 in Q3 2026.
- ↓High share volatility and elevated short interest reflect market skepticism.
- ↓Share price down over 50% YTD indicates deep sector weakness.
- ↓Negative growth factor warning suggests unreliable growth despite revenue rise.
- ↓Lack of U.S. plant-touch operations limits federal reform upside.
- ↓Poor quality metrics and small size raise financial health concerns.
Investment themes with TLRY
Drug development driving global healthcare solutions
Stocks with high short interest ratios
Stocks with highest short interest
Earnings Call · Q3 2026 · Mgmt. Guidance
Transcript signals
Bull points
- this quarter we achieved record third quarter revenue and strong year-over-year improvements in gross profit and adjusted EBITDA and we are reaffirming our adjusted EBITDA guidance for fiscal 2026.
- net revenue was a third quarter record of 206.7 million dollars an 11 increase year over year revenue growth was across multiple businesses Cannabis net revenue increased 19% year-over-year to $64.8 million during the quarter, driven by strong growth in gross international cannabis revenue of 73% and 8% in net Canadian adult use and medical cannabis.
- We expect distribution to continue to be a strong contributor as it complements and scales alongside our international business.
Bear points
- we overcame $7 million in price pressure that flows directly to the bottom line.
- price compression in international markets, which reduced international cannabis revenue by approximately $7 million despite higher gram equivalents sold.
- I think this represents the bottom.